Candidemia Market is expected to Grow by 2032, Delveinsight

A detailed review of historical and forecasted Candidemia market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Candidemia market.

Candidemia: An Overview
Candidemia is a serious, life-threatening bloodstream infection and possibly the fourth most common all-type bloodstream infections seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.

Request for sample and discover more about the Candidemia report offerings- https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions Covered in the Report
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Key Takeaways from Candidemia Market Report
• Age is an important factor in the progression of the disease. In 2020, there were >40% of the cases in the age group of 65 years and above, which was the highest in any age group in the US. This was followed by ~33% cases in the age group of 45-64 years.
• In 2020, 55% of incident candidemia patients were males whereas 45% were females, in Japan.
• Among the European countries, Spain had the highest population of candidemia with approximately 6,214 cases, followed by Germany, which had approximately 3,457 cases in 2020.

Candidemia Epidemiology Insights
According to DelveInsight's analysis, Candidemia is slightly more prominent in males in comparison to females. The United States has the highest percentage of candidemia patients. Reportedly, the incidence of candidemia varies among the different age groups. Age plays an important role in case of Candidemia, which is most common at an older age.

Candidemia Epidemiology Segmentation in the 7MM
• Total Candidemia Incident cases
• Candidemia Age-specific cases
• Candidemia Gender-specific cases
• Total patients receiving antifungal treatment targeting Candida
Get to know more about Candidemia epidemiology facts- https://www.delveinsight.com/sample-request/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Candidemia Market Analysis
DelveInsight's analysts estimate that the market is expected to show positive growth, mainly attributed to increased incidence and the anticipated launch of novel therapies, such as Fosmanogepix (Pfizer) and Rezafungin (Cidara Therapeutics/Mundipharma), during the forecast period (2022-2032).

Candidemia Market Insights
The term candidemia describes the presence of Candida infection in the blood. Candidemia is the most common manifestations of invasive candidiasis. Candida in a blood culture should never be viewed as a contaminant and should always prompt a search for the source of the bloodstream infection. For many patients, candidemia is a manifestation of invasive candidiasis that could have originated in a variety of organs, whereas for few, candidemia originated from an infected indwelling intravenous catheter. As candidemia can cause serious, life-threatening illness, treatment is usually begun when an infection is suspected. Treatment includes finding the infection source, and if possible, removing it (for example, the central venous catheter) and beginning treatment with anti-fungal medication.

Candidemia Treatment Market
The treatments used to manage Candida infections vary substantially. They are based on the anatomic location of the infection, the patients' underlying disease and immune status, the patients' risk factors for infection, the specific species of Candida responsible for the infection, and, in some cases, the susceptibility of the Candida species to specific antifungal drugs. The armamentarium of drugs for candidiasis treatment currently comprises three major drug classes: polyenes, azoles, and echinocandins.

Candidemia Emerging Drugs
• Rezafungin (CD101)
• Fosmanogepix (APX-001)
• Drug X

Candidemia Market Size
The market size shall increase during the forecast period (2022‒2032), owing to the launch of upcoming therapies. The market Size of candidemia in the 7MM is expected to be USD XX million in 2032.

Find a snapshot of the Candidemia Market Landscape Report- https://www.delveinsight.com/report-store/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Candidemia Market Access
Candidemia cases were more prevalent in pediatric and general surgery ICUs. The rates of non-albicans candidemia were also higher in these units. Higher mortality rates were observed in medical and general surgery ICUs. Fluconazole usage was higher in the ICUs. However, oral fluconazole was frequently used in the hematology department, which was calculated separately. Higher rates of fluconazole resistance were found in the hematology department. In conclusion, candidemia is still a significant problem with growing incidence, and institutions should determine problems related to infection control measures in developing countries. Each institution's policy against candidemia should be specified for Candidemia prevalence, resistance rates, antifungal use, and costs.

Candidemia Market Drivers
• Upcoming launch of novel, new class anti-fungal drugs
• Increasing awareness for treating Candidemia
• Personalized treatments

Candidemia Market Barriers
• Minimizing the use of anti-microbial
• Lack of adequate diagnosis
• Lack of country-specific guidelines

Candidemia Market Companies
• Amplyx Pharmaceuticals
• Cidara Therapeutics Inc.
• Scynexis, Inc., and Several Others

Table of Content
1. Key Insights
2. Executive Summary of Candidemia
3. Competitive Intelligence Analysis for Candidemia
4. Candidemia Market Overview at a Glance
5. Candidemia: Disease Background and Overview
6. Patient Journey
7. Candidemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Candidemia Unmet Needs
10. Key Endpoints of Candidemia Treatment
11. Candidemia Marketed Products
12. Candidemia Emerging Therapies
13. Candidemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Candidemia
17. KOL Views
18. Candidemia Market Drivers
19. Candidemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Get in Touch with our Business Consultant- https://www.delveinsight.com/report-store/candidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

This release was published on openPR.